Strides Pharma Science Ltd
Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 31 Jul 2026, 12:42 PM IST · BSE ID: 9c81e00e-f0cc-48dc-bf79-09540809ebbe
View Original BSE Filing (PDF)
💡
In Simple Terms
Strides Pharma's latest quarterly sales increased by 13% to ₹12,654 million, with good growth in international markets.
🤖 AI Summary
- Strides Pharma Science reported Q1FY27 revenue of ₹12,654m, marking a 13% year-on-year increase.
- Ex-US Markets revenue rose 17% YoY to ₹5,875m ($63m), driven by strong performance across regions.
- EBITDA increased 5.4% YoY to ₹2,298m, impacted by ₹131m in geopolitical freight and operating costs.
- Reported PAT grew 56.7% YoY to ₹1,655m, including a gain from the Pivot Path divestment.
- ₹1,000m of value was unlocked through the divestment of a majority stake in Pivot Path, its captive GCC.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Ex-US Markets revenue
₹5,875m
17% YoY
US business revenue
₹6,282m
4% YoY
Reported PAT
₹1,655m
56.7%
Operational PAT
₹1,231m
8.0%
Operational EPS
₹13.4
8.0%
Value unlocked from Pivot Path divestment
₹1,000m
🏢 How This Affects the Company
The company's diversified business strategy appears strengthened by the 17% YoY growth in Ex-US Markets, contributing ₹5,875m to Q1FY27 revenue. The US business maintained steady performance, growing 4% YoY to ₹6,282m.
Consolidated Q1FY27 revenue increased to ₹12,654m, with reported PAT significantly up by 56.7% YoY to ₹1,655m due to a divestment gain. The divestment of Pivot Path unlocked ₹1,000m in value.
Geopolitical disruptions resulted in a ~₹131m impact on freight and operating costs, requiring continuous cost optimization efforts. Despite this, the company achieved an EBITDA margin of 18.2%.
Geopolitical disruptions continue to pose a risk to operating and freight costs, as evidenced by the ~₹131m impact in Q1FY27. Management is focused on mitigating these pressures through cost optimization.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's financial performance impacts the underlying value of their holdings. Reported EPS for Q1FY27 was ₹17.0, up 57.6% YoY.
🔍
Management Signal
Management is focused on driving growth in Ex-US markets, mitigating geopolitical cost pressures through optimization, and strategically divesting non-core assets to unlock value.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — assess sustained growth in Ex-US markets.
Updates on geopolitical situation — observe impact on freight and operating costs.
Further details on cost optimization initiatives — check their effectiveness on margins.
MEDIUM RISK
Ongoing geopolitical disruptions impacting freight and operating costs, noted at ~₹131m, present a continued external risk.
💡 Investor Takeaway
Strides Pharma Science reported Q1FY27 revenue of ₹12,654m, up 13% YoY, with Ex-US Markets revenue growing 17% YoY to ₹5,875m. Reported PAT increased 56.7% YoY to ₹1,655m, partly driven by ₹1,000m value unlocked from a divestment.
⚖️ Strengths & Concerns
✅ Positives
- Revenue grew 13% YoY to ₹12,654m in Q1FY27, driven by a 17% YoY increase in Ex-US Markets revenue to ₹5,875m.
- Reported PAT increased by 56.7% YoY to ₹1,655m, partly due to unlocking ₹1,000m value from the Pivot Path divestment.
⚠️ Concerns
- EBITDA growth was 5.4% YoY at ₹2,298m, with a ~₹131m impact from geopolitical disruptions on operating costs.
- EBITDA % decreased by 130 bps YoY from 19.5% in Q1FY26 to 18.2% in Q1FY27.
📅 Company Track Record
Strides Pharma Science Ltd previously informed BSE on 2026-07-24 about the Board Meeting scheduled for July 31, 2026, to approve the Q1 FY27 results. This filing confirms the completion of that board meeting and the release of the results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Strides Pharma Science's revenue for Q1 FY27?
Strides Pharma Science reported a revenue of ₹12,654m for Q1 FY27, which is a 13% year-on-year growth.
How did Strides Pharma Science's Ex-US Markets perform in Q1 FY27?
Ex-US Markets revenue for Strides Pharma Science was ₹5,875m ($63m) in Q1 FY27, reflecting a strong 17% year-on-year growth.
What was the reported Net Profit (PAT) for Strides Pharma Science in Q1 FY27?
Strides Pharma Science's Reported PAT for Q1 FY27 was ₹1,655m, which is a 56.7% increase year-on-year.
What was the impact of geopolitical disruptions on Strides Pharma Science's Q1 FY27 results?
Geopolitical disruptions had an impact of approximately ₹131m on freight and operating costs for Strides Pharma Science in Q1 FY27.
What value did Strides Pharma Science unlock through divestment in Q1 FY27?
Strides Pharma Science unlocked ₹1,000m of value through the divestment of a majority stake in Pivot Path, its captive GCC, during Q1 FY27.
Questions based on this BSE filing only. For information purposes.